Clinical trial
A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614 is registered in ClinicalTrials.gov with Aridis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2a Randomized, Double-Blind, Two-Part, Dose-Ascending, Multicenter Study of the Safety and PK of AR-501 (Gallium Citrate), Administered Via Inhalation, in Healthy Adult and P. Aeruginosa Infected Cystic Fibrosis Subjects
- Lead sponsor
- Aridis Pharmaceuticals, Inc.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 7, 2018
- Completion date
- July 31, 2023
- Enrollment
- 102 (estimated)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.